Xcout Intel
Angitia Biopharmaceuticals
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases.
Subscribe to see Angitia Biopharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Angitia Biopharmaceuticals at a glance
Angitia Biopharmaceuticals is a biotech company headquartered in United States. Xcout tracks 9 named people at Angitia Biopharmaceuticals, including Hua Zhu (David) Ke (Founder, Chairman, Chief Executive Officer).
Angitia Biopharmaceuticals leadership
- Hua Zhu (David) KeFounder, Chairman, Chief Executive Officer
- Willard DereChief Medical Officer, Chief Advisor to CEO
- Mike ArenbergChief Financial Officer
- Lei ZhengChief Technology Officer
- Ann ZoveinChief Scientific Officer
- Muyu (Luna) LiCo-founder, Chief Operating Officer
3 more named people on record for Angitia Biopharmaceuticals, with roles, board committees and tenure — see the full roster →
Angitia Biopharmaceuticals competitors
A few of Angitia Biopharmaceuticals's closest competitors — see the full list of competitors and alternatives →
Engitix is a biotechnology company that utilizes a proprietary platform based on human Extracellular Matrix (ECM) scaffolds to model and study disease biology. The company develops discovery-stage therapeutics targeting fibrosis, inflammation, and solid tumors, and forms partnerships with pharmaceutical and biotech organizations.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Augustine Therapeutics is a biotechnology company focused on developing selective HDAC6 inhibitors for the treatment of neuromuscular, neurodegenerative, and cardiometabolic diseases.
Atrogi is a clinical-stage biotechnology company headquartered in Stockholm, Sweden, pioneering the development of novel treatments for metabolic disorders.
Keros Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics targeting the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company focuses on creating treatments for patients with hematological and neuromuscular disorders linked to dysfunctional protein signaling.
Amplicore Inc. develops injectable therapeutics aimed at treating degenerative musculoskeletal disorders such as osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears. The company focuses on regenerative and minimally invasive approaches to address the underlying causes of joint discomfort and restore mobility for patients.
Get Angitia Biopharmaceuticals's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Angitia Biopharmaceuticals? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Angitia Biopharmaceuticals in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access